4 Results for "

skeletal metastases

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "skeletal metastases" in MCE Product Catalog:

Cat. No.: HY-W008951
CAS No.: 1429-50-1
Synonyms: EDTMP
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .
loading...
    loading...
Cat. No.: HY-16498
CAS No.: 848084-83-3
Synonyms: PCK-3145
Target:  

Apoptosis PTHR

Research Areas:  

Metabolic Disease Cancer

Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia .
loading...
    loading...
Cat. No.: HY-129246
CAS No.: 21739-91-3
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Cytembena is inhibitor for replicative DNA synthesis, purine synthesis and tetrahydrofolate formylase activity. Cytembena ameliorates ovarian or breast cancer, relieves the pain from skeletal metastases .
loading...
    loading...
Cat. No.: HY-16497
CAS No.: 848084-84-4
Synonyms: PCK 3145 TFA
Target:  

Apoptosis PTHR

Research Areas:  

Metabolic Disease Cancer

Tigapotide TFA (PCK-3145 TFA) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide TFA inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide TFA induces Apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide TFA inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide TFA reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide TFA is applicable for the research of prostate cancer and malignancy-associated hypercalcemia .
loading...
    loading...